Objective: To provide an up-to-date review of the etiology, epidemiology, clinical features, diagnostic findings, and treatment options for systemic lupus erythematosus (SLE).
Data Sources: A PubMed search of English language articles using a combination of words: elderly, systemic lupus erythematosus*, late onset systemic lupus erythematosus*, etiology, screening, diagnosis, or treatment to identify original studies, guidelines, and reviews on systemic lupus erythematosus, SLE, and late onset systemic lupus erythematosus, published 2000 to present.
Study Selection And Data Extraction: Original studies, clinical reviews, references, and guidelines were obtained and evaluated on their clinical relevance.
Data Synthesis: The literature included guidelines and considerations for the etiology, diagnosis, screening, and management of SLE.
Conclusion: SLE is a chronic autoimmune disorder. It predominantly affects younger women, but can occur in up to 20% of patients 50 years of age or older. SLE affects almost every system in the body, with varying degrees of severity. The diagnosis is based on criteria set by the American College of Rheumatology. Management is individualized and depends on presenting symptoms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4140/TCP.n.2013.110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mendelian randomization analysis does not support a causal influence between lipoprotein(A) and immune-mediated inflammatory diseases.
Sci Rep
January 2025
State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.
Observational studies have reported an association between lipoprotein(a) (Lp(a)) and immune-mediated inflammatory diseases (IMIDs). This study used Mendelian Randomization (MR) and multivariable MR (MVMR) to explore the causal relationship between lipoprotein(a) [Lp(a)] and immune-mediated inflammatory diseases (IMIDs). We performed a bidirectional two-sample mendelian randomization analyses based on genome-wide association study (GWAS) summary statistics of Lp(a) and nine IMIDs, specifically celiac disease (CeD), Crohn's disease (CD), ulcerative colitis (UC), inflammatory bowel disease (IBD), multiple sclerosis (MS), psoriasis (Pso), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), and summary-level data for lipid traits.
View Article and Find Full Text PDFSevere pulmonary arterial hypertension and cardiogenic shock in acute systemic lupus erythematosus.
BMJ Case Rep
January 2025
Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia.
We describe a woman in her late 20s with newly diagnosed systemic lupus erythematosus (SLE), who presented with fulminant pulmonary arterial hypertension (PAH) requiring inotropic and extracorporeal support. She was established on triple pulmonary vasodilator therapy with concurrent aggressive immunosuppression; however, treatment was complicated by infection and diffuse alveolar haemorrhage, necessitating delays in immunosuppression and withdrawal of epoprostenol. Despite this, with ongoing suppression of her SLE, her pulmonary haemodynamics improved, with normal pressures on right heart catheterisation several months later allowing stepdown to sildenafil monotherapy.
View Article and Find Full Text PDFMedication-related hospitalisations in patients with SLE.
Lupus Sci Med
January 2025
Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
Objectives: Patients with SLE take multiple medications. Within a large prospective longitudinal SLE cohort, we characterised medication-related hospitalisations and their preventability.
Methods: We identified consecutive admissions to our tertiary hospitals between 2015 and 2020.
Letter re: Laryngeal and voice dysfunction in systemic lupus erythematosus patients - A case-control study.
Lupus
January 2025
Rheumatology Department, Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal.
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus.
Rheumatology (Oxford)
January 2025
Division of Nephrology, Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease; State Key Laboratory of Organ Failure Research; Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangdong Laboratory, Guangzhou, 510515, China.
Objectives: The relationship between proteomic profiles and incident systemic lupus erythematosus (SLE) remains unclear. We aimed to identify candidate plasma proteins for SLE risk in women, discover potential treatment targets for SLE, and develop and validate a protein-based prediction model for SLE risk.
Methods: 28 220 women from the UK Biobank were randomly split into training (70%) and testing (30%) sets.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!